Prescription Biosimilars

Discover the latest insights and strategies for managing prescription biosimilar therapies. This course will explore the key benefits and tackle the challenges of biosimilar adoption. Gain knowledge in therapeutic areas where biosimilars are transforming care. This CME course is intended exclusively for UC learners.

Topics:

• Biosimilar coverage across payers
• Interchangeability
• Safety and efficacy
• Value-based care
• Clinical experience

Registration Fee

Free (UC Learner Only)*

*This course is exclusively for UC learners. During registration, you will be asked to provide your UC-affiliated email address for verification. Registrations submitted without this information or those that fail validation will be automatically canceled.

Cancellation Policy
All cancellations must be submitted in writing via email to  ccpd@mednet.ucla.edu to ensure accurate tracking of registrants.

Course Recording
The course recording will be made available as an enduring material course after the course.

Target Audience

Specialties - Health Care Administration, Leadership, and Management

Professions - Administrator, Fellow, Fellow/Resident, Medical Student, Nurse, Pharmacist, Pharmacy Technician, Physician, Physician Assistant, Quality Improvement Professional, Resident, Scientist/ Researcher

Objectives

At the conclusion of this activity, learners will be able to:

1. Identify the range of FDA-approved prescription biosimilars available for treating chronic conditions.
2. Explain the regulatory approval process and clinical evidence supporting prescription biosimilars efficacy and safety.
3. Demonstrate the ability to integrate prescription biosimilars into patient treatment plans, considering individual patient needs and preferences.
4. Assess the impact of prescription biosimilar adoption on healthcare costs and patient outcomes, with a focus on the California patient population.
5. Develop strategies to address operational and clinical barriers to prescription biosimilar adoption within healthcare settings.
6. Critically evaluate the effectiveness of implemented strategies in improving prescription biosimilar utilization and reducing health disparities.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of David Geffen School of Medicine at UCLA and University of California Office of the President. The David Geffen School of Medicine at UCLA is accredited by the ACCME to provide continuing medical education for physicians.

The David Geffen School of Medicine at UCLA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.